Fig. 6From: Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerAntitumor activity of TAK-960 alone and in combination with Cetuximab or Irinotecan in CRC Patient-Derived Xenograft Models. a, b KRAS wt PDX models TAK-960 5 mg/kg + Cetuximab 0.4 mg/mouse. c, d In KRAS mut PDX models TAK-960 5 mg/kg, + Irinotecan 15 mg/kgBack to article page